{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"The study was designed to detect a 33.3% improvement in median survival time across treatments with one-sided type I error of 0.025 and 80% power.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0003","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"49.1","upperLimit":"72.8","value":"57.6"},{"groupId":"OG001","lowerLimit":"34.4","upperLimit":"49.1","value":"44.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"397"},{"groupId":"OG001","value":"393"}],"units":"Participants"}],"description":"Overall survival is defined as the time from randomization to death or date last known alive. Survival data reflects the database as of December 23, 2013.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \\[LHRH\\] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Androgen-Deprivation Therapy and Docetaxel"},{"description":"Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \\[LHRH\\] agonist therapy, LHRH antagonist therapy, or surgical castration).","id":"OG001","title":"Androgen-Deprivation Therapy Alone"}],"paramType":"MEDIAN","populationDescription":"All randomized patients","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months if patient is < 2 years from study entry; every 6 months if patient is 2 - 5 years from study entry; then annually if patient is 5 - 10 years from study entry","title":"Overall Survival","type":"PRIMARY","unitOfMeasure":"months"}